By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary ...
It could prove to be a case of better later than never for the healthcare giant.
The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...
Things are going from bad to worse for the pharmaceutical giant.
SHANGHAI, June 29 (Reuters) - Pfizer's ecnoglutide and Innovent Biologics' mazdutide have passed a preliminary review to be ...
The sizable yield comes with a concerning footnote. Just look at the rest of the story.
U.S. District Judge M. Casey Rodgers, in the Northern District of Florida, postponed her expert ruling this month due to a ...
Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.
Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and ...
Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.
Pfizer said on Monday its drug for a type of lung cancer missed the main goal of improving survival in patients compared to ...
Pfizer said on Thursday that finance chief Dave Denton will leave on August 15 to return to the consumer goods industry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results